Bayer on track in operational business

Group sales increase by 0.9 percent (Fx& portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx& portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase by 5.9 percent to 1.62 euros / Group outlook confirmed yet increasingly ambitious
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news